Alligator Bioscience AB Reports Strong Q4 and Full Year 2024 Results

Generado por agente de IAMarcus Lee
miércoles, 22 de enero de 2025, 2:42 am ET1 min de lectura
AB--
TOI--


Alligator Bioscience AB, a Sweden-based biotechnology company, has reported its full year and Q4 2024 financial results, showcasing significant progress in its immuno-oncology pipeline and a strong finish to the year. The company's lead asset, mitazalimab, demonstrated promising clinical and biomarker results, while cost-reduction programs and strategic initiatives have bolstered its financial position.

Comentarios



Add a public comment...
Sin comentarios

Aún no hay comentarios